Narumol Jarernsiripornkul

Prof. Dr. Narumol Jarernsiripornkul

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2014 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
NCNataporn Chaipichit
Nataporn Chaipichit
JKJanet Krska
Janet Krska
TPThongchai Pratipanawatr
Thongchai Pratipanawatr
VUVerawan Uchaipichat
Verawan Uchaipichat
NJNarumol Jarernsiripornkul
Narumol Jarernsiripornkul

15 January 2009 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
NJNarumol Jarernsiripornkul
Narumol Jarernsiripornkul
WKW. Kakaew
W. Kakaew
WLW. Loalukkana
W. Loalukkana
JKJ. Krska
J. Krska

Warisara JiamsathitWarisara Jiamsathit
Warisara Jiamsathit
ACAnthony R. Cox
Anthony R. Cox
SKSirinya Kampichit
Sirinya Kampichit
NJNarumol Jarernsiripornkul
Narumol Jarernsiripornkul
Adverse drug reaction (ADR) severity levels are mainly rated by healthcare professionals (HCPs), but patient ratings are limited. This study aimed to compare patient-rated and pharmacist-rated ADR severity levels and determined methods employed for ADR management and prevention by patients and HCPs. A cross-sectional survey was conducted in outpatients visiting two hospitals. Patients were asked about ADR experiences using a self-administered questionnaire, and additional information was retrieved from the medical records. In total, 617 out of 5594 patients had experienced ADRs (11.0%), but 419 patients were valid (68.0%). Patients commonly reported that their ADR severity level was moderate (39.4%), whereas pharmacists rated the ADRs as mild (52.5%). There was little agreement between patient-rated and pharmacist-rated ADR severity levels (κ = 0.144; p < 0.001). The major method of ADR management by physicians was drug withdrawal (84.7%), while for patients, it was physician consultation (67.5%). The main methods for ADR prevention by patients and HCPs were carrying an allergy card (37.2%) and recording drug allergy history (51.1%), respectively. A higher level of ADR bothersomeness was associated with higher ADR severity levels (p < 0.001). Patients and HCPs rated ADR severity and used ADR management and prevention methods differently. However, patient rating of ADR severity is a potential signal for severe ADR detection of HCPs.

10 June 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
Warisara JiamsathitWarisara Jiamsathit
Warisara Jiamsathit
ACAnthony R. Cox
Anthony R. Cox
NJNarumol Jarernsiripornkul
Narumol Jarernsiripornkul
Healthcare professionals (HCPs) play a key role in the monitoring of severe adverse drug reactions (ADRs). The present study aims to explore practices and barriers of HCPs in severe ADR monitoring and reporting, to evaluate their attitudes towards the monitoring and to assess the related factors. Self-administered questionnaires produced in hard copy and Google form were sent to 510 HCPs by stratified random sampling. Of the 350 HCPs that responded (68.6%), 44.9% had ever monitored ADRs. The most common practices were the observation of abnormal symptoms for ADR identification (88.5%), discontinuation of the suspected drug for ADR management (88.5%) and advice on recurrent drug allergy for ADR prevention (88.5%). Most HCPs (93.0%) obtained further patient history to identify severe ADRs. The uncertainty of the causal relationship was a major barrier to ADR reporting (60.0%). Pharmacists were more involved with practices in ADR monitoring and reporting (OR 20.405; p < 0.001), whereas longer work experience (>20 years) was negatively related to the practices (OR 0.271; p = 0.024). Over one-third (37.6%) of HCPs had a positive attitude towards severe ADR monitoring. In conclusion, the practices in severe ADR monitoring varied among different professions. However, the barriers to the reporting of ADRs still exist; hence, improving knowledge and cooperation among HCPs should be promoted.

1 June 2003 in European journal of pain
Verified
Journal Article
Closed access
PDF file
NJNarumol Jarernsiripornkul
Narumol Jarernsiripornkul
JKJanet Krska
Janet Krska
RRR. Michael E. Richards
R. Michael E. Richards
PCPhillip A.G. Capps
Phillip A.G. Capps

4 July 2009 in Pharmacy World & Science
Verified
Journal Article
Closed access
PDF file
NJNarumol Jarernsiripornkul
Narumol Jarernsiripornkul
SCSudarat Chaisrisawadsuk
Sudarat Chaisrisawadsuk
ACAporanee Chaiyakum
Aporanee Chaiyakum
JKJanet Krska
Janet Krska